ALT program
Cancers with Alternative Lengthening of Telomeres (ALT) mechanism
Pre-clinicalActive
Key Facts
Indication
Cancers with Alternative Lengthening of Telomeres (ALT) mechanism
Phase
Pre-clinical
Status
Active
Company
About Tessellate BIO
Tessellate Bio is an early-stage biotech pioneering the next frontier of synthetic lethality in oncology, targeting mechanisms beyond the well-established HRD pathway. The company has two disclosed preclinical programs targeting Alternative Lengthening of Telomeres (ALT) and RB1 Loss-of-Function, and has secured a significant partnership with Boehringer Ingelheim. Backed by top-tier European investors and led by a seasoned team of drug hunters, Tessellate aims to create highly tumor-targeted treatments for hard-to-treat cancers.
View full company profile